Literature DB >> 2897996

Involvement of the somatostatin and cholinergic systems in the mechanism of growth hormone autofeedback regulation in the rat.

A Torsello1, G Panzeri, P Cermenati, M C Caroleo, E Ghigo, F Camanni, E E Müller, V Locatelli.   

Abstract

The involvement of the cholinergic system in GH secretion has recently acquired increasing importance. Data have been presented suggesting that in rats the effect of cholinergic modulation on GH secretion takes place through inhibition or stimulation of hypothalamic somatostatin (SRIF) release. To investigate further the significance of cholinergic-SRIF link and its role in the regulation of GH secretion, the action of cholinergic agonist and antagonist drugs in the GH short-loop feedback mechanism mediated by SRIF was investigated. Intracerebroventricular (i.c.v.) infusion of 0.2 or 2.0 micrograms GH/rat into the lateral brain ventricle of adult male rats induced a significant reduction in the GH-releasing hormone (GHRH; 2 micrograms/kg, i.v.)-induced peak GH rise, but only the 2.0 micrograms dose reduced also the GH-integrated area after administration of GHRH. This effect was absent after central administration of 20.0 micrograms GH/rat, due probably to leakage of some GH from the cerebral ventricle into the systemic circulation. Pretreatment with cysteamine (300 mg/kg, s.c.), a known depletor of hypothalamic SRIF, or with anti-SRIF serum (0.5 ml/rat) completely counteracted the lessening of the GH response to GHRH induced by 2.0 micrograms GH injected i.c.v. Similarly, pretreatment with the cholinergic agonist pilocarpine (3 mg/kg, i.v.) completely antagonized the inhibitory effect of central infusion of GH on the GHRH-induced GH response. Atropine (1.0 mg/kg, i.v.), a muscarinic cholinergic antagonist, strikingly inhibited the GHRH-induced GH rise, but when given in combination with i.c.v. infusion of GH there was no additive inhibitory effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897996     DOI: 10.1677/joe.0.1170273

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  12 in total

1.  Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome.

Authors:  K Hanew; A Tanaka; A Utsumi
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

2.  Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I. A study on ad libitum fed and starved adult male rats.

Authors:  M C Ghigo; A Torsello; R Grilli; M Luoni; M Guidi; S G Cella; V Locatelli; E E Müller
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

3.  The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.

Authors:  J Bellone; S Bellone; G Aimaretti; M R Valetto; C Baffoni; G Corneli; C Origlia; E Arvat; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

4.  Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations?

Authors:  S Vannelli; B Stasiowska; J Bellone; G Aimaretti; S Bellone; T Avataneo; S Cirillo; L Benso
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

5.  Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors:  E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

6.  A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.

Authors:  E Ghigo; S Goffi; E Arvat; E Imperiale; G M Boffano; M R Valetto; E Mazza; I Santi; A Magliona; M F Boghen
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

Review 7.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

8.  Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Authors:  M Cappa; S Setzu; S Bernardini; D Carta; G Federici; A Grossi; S Loche
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

9.  The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly.

Authors:  K Hanew; A Utsumi; A Sugawara; Y Shimizu; H Ikeda; K Abe
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

10.  Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa.

Authors:  S Fassino; F Lanfranco; G Abbate Daga; V Mondelli; S Destefanis; G G Rovera; F Camanni; E Ghigo; E Arvat; L Gianotti
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.